Trial reports tumor shrinkage and some complete responses from amivantamab in treatment-resistant head and neck cancer

Who was included in this trial?

The trial involved 102 patients with recurrent or metastatic head and neck cancer whose disease had spread or returned and was no longer responding to standard treatment, including chemotherapy and immunotherapy Independent,il Giornale.it,Metro,Irish Times.

What results were reported?

Across reports on the study, amivantamab was said to shrink tumors in 42% of patients, and doctors reported complete tumor disappearance in 15 patients Mirror,ITV Hub,Metro,Irish Times.

Why are these findings getting attention?

The results concern a patient group whose cancer had already stopped responding to existing treatments, so any evidence of tumor shrinkage or complete response could point to a new option where few remain; however, the evidence cited here comes from a clinical trial, so more research is needed Independent,Metro,Irish Times.